Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLC901 (NeuroAiD™ II) in Patients With Mild to Moderate Ischemic Stroke
NCT07828210Phase 4Recruiting
- Sponsor
- EVD Pharmacy and Medical
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mlc901 in ischemic stroke (2 arms), sponsored by EVD Pharmacy and Medical. Primary endpoints: EuroQol 5-Dimension 5-Level at Day 14, EuroQol Visual Analogue Scale at Day 14 and 3 more. Started Sep 2026; status: recruiting.
02
Drugs
mlc901
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07828210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828210.